-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Clinical Implications of the Duffy Antigen

Program: Spotlight Sessions
Session: What is a “Normal” Neutrophil Count? The Duffy Red Cell Antigen, Ancestry, Genetics and Evolution
Hematology Disease Topics & Pathways:
Diversity, Equity, and Inclusion (DEI) , hematopoiesis, Biological Processes
Monday, December 11, 2023, 2:45 PM-4:00 PM

John Mark Sloan, MD

Boston University School of Medicine, Boston, MA

Disclosures: Sloan: Seagen: Research Funding; Servier Pharmaceuticals: Honoraria; Stemline Pharmaceuticals: Consultancy; Nuvectis Pharaceuticals: Consultancy; Abbvie: Consultancy; CTI Biopharma: Honoraria.

<< Previous Presentation | Next Presentation